Systemic immunosuppression in times of COVID-19: do we need to rethink our standards?

The current SARS-CoV-2 pandemic particularly endangers older people with pre-existing cardiopulmonary and metabolic conditions. However, it is also currently under discussion whether patients under immunosuppressive therapy also have a higher risk of suffering a severe course of the COVID-19 disease...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Grabbe, Stephan (Autor) , Beissert, Stefan (Autor) , Enk, Alexander (Autor)
Formato: Article (Journal)
Lenguaje:inglés
Publicado: 21 August 2020
In: Journal der Deutschen Dermatologischen Gesellschaft
Year: 2020, Volumen: 18, Número: 8, Pages: 810-813
ISSN:1610-0387
DOI:10.1111/ddg.14194
Acceso en línea:Verlag, kostenfrei, Volltext: https://doi.org/10.1111/ddg.14194
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/ddg.14194
Enlace del recurso
Notas de Autor:Stephan Grabbe, Stefan Beissert, Alexander Enk
Descripción
Sumario:The current SARS-CoV-2 pandemic particularly endangers older people with pre-existing cardiopulmonary and metabolic conditions. However, it is also currently under discussion whether patients under immunosuppressive therapy also have a higher risk of suffering a severe course of the COVID-19 disease. In principle though, there is currently no data available for a general reduction or pause of immunosuppression in patients with autoimmune diseases because of the SARS-CoV-2 pandemic. However, since there is currently neither an effective therapy nor corresponding vaccination protection, the indication for a prolonged immunosuppressive therapy should be made with special care. In particular, immunotherapeutic agents that produce long-term effects (e.g., rituximab) should be used with special caution. In contrast, immunomodulating substances that do not suppress antiviral immunity (e.g. systemic immunoglobulins, doxycycline), or that have intrinsic effects on SARS-CoV-2 (calcineurin inhibitors, chloroquine, hydroxychloroquine) may be useful alternatives.
Notas:Gesehen am 13.07.2026
Descripción Física:Online Resource
ISSN:1610-0387
DOI:10.1111/ddg.14194